


Organised by:



PEER REVIEW LEARNING SESSION ON BREAST CANCER

Date: 4 February 2026

Time: 6:00 pm - 9:00 pm

SAFRA - MOUNT FABER
(CRYSTAL ROOM)

PROGRAMME

MODERATORS: DR JOLINE LIM (CURIE); DR JACK CHAN (NCCS)

6:30 PM	Registration
7:00 PM	Welcome Address by Chapter Chairman, Dr Tham Chee Kian
7:05 PM	Session 1: aTNBC (25 min) 5 min - ASCENT-04/KEYNOTE-D19: 1L Sacituzumab Govitecan vs Chemo + Pembrolizumab for PD-L1+ aTNBC (ASCO 2025) 5 min - TROPION-Breast02: 1L Datopotamab Deruxtecan vs Chemo for aTNBC Ineligible for PD-(L)1 ICIs (ESMO 2025) Presenters: Dr Toh Ching Han, Dr Ong Zheng Xuan 15 min - Discussion Discussants: Dr Rebecca Dent /Dr Karmen Wong
7:30 PM	Session 2: HER2+ ABC (25 min) 5 min - DESTINY-Breast09: 1L Trastuzumab Deruxtecan + Pertuzumab vs THP for HER2+ ABC (ASCO 2025, ESMO 2025) 5 min - HER2CLIMB-05: 1L Maintenance Tucatinib vs placebo + HP for HER2+ MBC (SABCS 2025) Presenters: Dr Xu Yanning, Dr Stephanie Tan Wei Lin 15 min - Discussion Discussants: Dr Elaine Lim Hsuen / Dr Lim Jian Ri
7:55 PM	Session 3: HR+ HER2- BC (25 min) 5 min - SERENA-6: Camizestrant vs Continued AI + CDK4/6i After ESR1 mut in HR+ HER2- ABC (ASCO 2025) 5 min - IIdERA : Adjuvant Giredestrant vs SOC ET in ER+ HER2- EBC (SABCS 2025) Presenters: Dr Victor Lee, Dr Wang Meng 15 min Discussion Discussants: Dr Lee Soo Chin / Dr Samuel Ow/Dr Khoo Kei Siong
9:00PM	Closing Remarks and end of event

To register:



Sponsored by:

